ACHV - Achieve Life Sciences, Inc.
| Previous Close | 1.9100 |
| Open | 1.9100 |
| Bid | 1.8800 x 1200 |
| Ask | 2.0600 x 900 |
| Day's Range | 1.8800 - 1.9650 |
| 52 Week Range | 1.0400 - 5.2500 |
| Volume | 9,311 |
| Avg. Volume | 244,034 |
| Market Cap | 14.712M |
| Beta (3Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1910 |
| Earnings Date | Jun 10, 2019 - Jun 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Simply Wall St.•10 days ago
Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
- Benzinga•29 days ago
Achieve Life Sciences Says Mid-Stage Data For Smoking Cessation Drug Accepted For Presentation At Conference
Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV ) traded sharply higher Friday morning before paring those gains. Achieve, which develops Cytisinicline – a plant-based ...
- PR Newswire•29 days ago
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019. The abstract "A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers" and oral presentation will include updated cytisinicline data from the recently completed ORCA-1 trial. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.
- Zacks Small Cap Research•last month
ACHV: ORCA-1 Topline Results and Comparison
Achieve Life Sciences, Inc. (ACHV) reported topline results from its Phase IIb Ongoing Research of Cytisinicline for Addiction (ORCA)-1 trial which was launched in October 2018. The study enrolled 254 subjects, employing six arms: four with active drug and two with placebo. The primary endpoint for the ORCA-1 study was the self-reported reduction in daily smoking.
- PR Newswire•last month
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
SEATTLE and VANCOUVER, British Columbia, June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The primary endpoint was the reduction in daily smoking, a self-reported measure. Three of the four cytisinicline treatment arms demonstrated a statistically significant improvement, as defined in the protocol as p
- PR Newswire•2 months ago
Achieve Receives $4.2 Million from Exercise of Warrants
SEATTLE and VANCOUVER, British Columbia, June 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it entered into an agreement with a single investor to exercise outstanding warrants that will provide an aggregate of $4.2 million in total proceeds. The proceeds from the warrant exercise would bring Achieve's pro-forma cash balance to approximately $13.9M as of March 31, 2019, based on its most recently reported financial results. Pursuant to the agreement, the investor agreed to exercise outstanding warrants to purchase 270,313 shares of the Company's common stock, with an exercise price of $3.1445 per share and outstanding warrants to purchase 837,500 shares of Common Stock with an exercise price of $4.00 per share.
- Zacks Small Cap Research•2 months ago
ACHV: 1Q:19 Financial & Operational Update
Achieve Life Sciences, Inc. (ACHV) released its first quarter results for 2019 and filed the companion 10-Q on May 15, 2019. Since our previous update two months ago, the company announced the end of the ORCA-1 trial which is expected to produce topline results mid-year.
- PR Newswire•2 months ago
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
SEATTLE and VANCOUVER, British Columbia, May 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (No. 10,300,050) on succinate salt of cytisinicline and use thereof. Applications are pending in the European Patent Office, Japan, China, Australia, Canada, and South Korea. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.
- PR Newswire•2 months ago
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results. The primary efficacy endpoint is reduction in the number of cigarettes smoked during treatment with secondary analyses to be conducted on smoking cessation rates, safety, and compliance.
- PR Newswire•2 months ago
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research•3 months ago
ACHV: Final Enrollee, Final Visit
Achieve Life Sciences, Inc. (ACHV) announced that its final enrollee had completed their final visit in the Phase IIb ORCA-1 trial on Wednesday. As a reminder the ORCA-1 (Ongoing Research of Cytisinicline for Addiction) trial is evaluating the effectiveness of cytisinicline for smoking cessation. The trial was designed as a multicenter, double blind, placebo-controlled trial in adult smokers randomized in a 2:2:1 ratio at 1.5 mg, 3.0 mg and placebo.
- PR Newswire•3 months ago
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications.
- PR Newswire•4 months ago
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
SEATTLE, Wash. and VANCOUVER, British Columbia , April 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development ...
- Benzinga•4 months ago
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- PR Newswire•4 months ago
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Data Safety Monitoring Committee (DSMC) met on March 28, 2019 to conduct its second and final safety review of the ORCA-1 Trial. The DSMC is an independent committee that advises on continuation or stopping of clinical trials based upon safety and study conduct considerations. The ORCA-1 DSMC has had the responsibility for safeguarding the interests of trial subjects by assessing the safety of the interventions and monitoring the conduct of the ORCA-1 trial.
- Zacks Small Cap Research•4 months ago
ACHV: Fiscal Year 2018 Operational and Financial Results
Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.
- ACCESSWIRE•4 months ago
What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on Achieve Life Sciences, Inc. (ACHV), a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic. On March 14th, the company provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. 2018 was a remarkable year of executing on the development plan for cytisinicline as a treatment for nicotine addiction and as an aid to smoking cessation.
- PR Newswire•4 months ago
Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time.
- ACCESSWIRE•4 months ago
Four Healthcare Stocks Picking Up Speed On Friday
CORAL GABLES, FL / ACCESSWIRE / March 15, 2019 / The future successes of the healthcare stock market are intrinsically entwined with whether, or not, healthcare companies are aptly prepared to rise to ...
- PR Newswire•4 months ago
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia , March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research•4 months ago
ACHV: A Reason to Quit is a Reason to Buy
Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.
